Novato, CA, United States of America

Kayvan R Niazi

USPTO Granted Patents = 90 

 

 

Average Co-Inventor Count = 3.4

ph-index = 5

Forward Citations = 111(Granted Patents)

Forward Citations (Not Self Cited) = 88(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Novato, CA (US) (2011 - 2017)
  • Encino, CA (US) (2014 - 2023)
  • Los Angeles, CA (US) (2016 - 2023)
  • Agoura Hills, CA (US) (2019 - 2024)
  • Culver City, CA (US) (2020 - 2024)

Company Filing History:


Years Active: 2011-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Neoepitope Presentation
Messenger RNA Production
Live Cell Imaging
Tumor Characterization
Mesenchymal Stem Cells
Cellular Adjuvants
HIV Treatment
SARS-CoV-2 Vaccines
T Cell Expansion
Chimeric Antigen Receptors
Immunogenic Modulation
Cancer Immunotherapies
90 patents (USPTO):Explore Patents

Title: Kayvan R Niazi: Innovating for a Safer Future

Introduction:

In the world of innovation and patents, Kayvan R Niazi stands out as a remarkable individual with a wealth of expertise. With a strong focus on developing cutting-edge solutions, Mr. Niazi has contributed significantly to the field of immunology and therapeutic advancements. Based in Novato, CA, he has made significant contributions to the fight against COVID-19 and advancements in immune therapies. Let's explore his latest patents, career highlights, collaborations, and his impactful work.

Latest Patents:

Kayvan R Niazi has an impressive portfolio, with 61 patents to his name. One of his latest patents is a groundbreaking method for inducing immunity against SARS-CoV-2, the virus responsible for the COVID-19 pandemic. This patent presents a novel approach utilizing spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus. The technique involves administering a vaccine composition via oral administration, nasal injection, nasal inhalation, oral inhalation, or even oral ingestion. Another aspect of this patent focuses on the development of compositions and methods for prevention and treatment of coronavirus diseases.

Another notable patent by Mr. Niazi focuses on anti-CD30 monoclonal antibodies and chimeric antigen receptors. These molecules demonstrate specific binding activity against CD30, making them particularly valuable for immune therapy. These innovations hold great potential for patients diagnosed with hematopoietic malignancies such as Hodgkin lymphoma, CD30-positive B cell lymphomas, CD30-positive T cell lymphomas, and CD30-positive NK cell lymphomas.

Career Highlights:

Throughout his career, Kayvan R Niazi has made significant contributions to the field of biotechnology and healthcare. As a recognized innovator, he has held notable positions at companies such as Nant Holdings IP, LLC and Nantbio, Inc. These organizations focus on developing transformative technologies and solutions to address critical healthcare challenges.

Collaborations:

Mr. Niazi has collaborated with esteemed professionals in his field, including Shahrooz Rabizadeh and Patrick Soon-Shiong. Such collaborative efforts allow for the exchange of ideas and expertise, further fueling innovation and pushing the boundaries of what is possible.

Conclusion:

Kayvan R Niazi exemplifies the spirit of innovation and dedication to improving global health. With an impressive patent portfolio and career spanning impactful roles at renowned biotechnology companies, his contributions in the areas of immunology and therapeutic advancements are invaluable. Collaborations with esteemed colleagues demonstrate his commitment to interdisciplinary approaches in pursuit of groundbreaking solutions. As Mr. Niazi continues to push boundaries, we can look forward to more life-changing innovations from this exceptional inventor.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…